Endocrinology and Metabolism
Hypocalcemia
1. What perinatal factors are associated with hypocalcemia in the immediate newborn period?
Transient congenital hypoparathyroidism
Congenital absence or hypoplasia of the parathyroid glands (sporadic or as part of DiGeorge syndrome)
2. How are calcium levels expected to change in premature infants during the first few days of life?
In newborn infants there is a physiologic decline in serum total and ionized calcium during the first 48 hours of life. This decline is exaggerated in preterm infants compared with term infants, with a direct correlation between serum calcium and gestational age ( Fig. 8-1). Because no symptoms are specific for early hypocalcemia in preterm infants, the diagnosis is made by demonstrating a serum calcium level below 7 mg/dL (1.75 mmol/L).
Figure 8-1 Serum calcium in relation to gestational age at 24 hours of age. (From Tsang RC, Light IJ, Sutherland JM, et al. Possible pathogenetic factors in neonatal hypocalcemia of prematurity. J Pediatr 1973;82:423–9.)
Hypocalcemia of prematurity is usually asymptomatic.
Long-term follow-up studies have shown no benefit with treatment.
Total serum calcium level is a poor predictor of ionized serum calcium in premature infants.
Intravenous (IV) calcium is associated with complications such as cardiac arrhythmias and ulcerations as a result of soft-tissue infiltration of the infusate. ∗†
Recent studies in premature infants using stable isotopes of calcium showed a true calcium absorption rate of 50% to 90%. Thus to meet an accretion rate of 100 mg/kg/day with an absorption rate of 75% and an assumed retention rate of 75% (which may be on the high side), oral intake of calcium for growing premature infants should be about 200 mg/kg/day. This large intake in infants with very low birth weight can be achieved only with special formulas for low-birth-weight infants or mineral fortifiers for breast milk–fed preterm infants. ∗
Hypercalcemia
23–27 weeks: 10.0 +/−1.0 (8.1–11.9)
28–31 weeks: 10.2 +/−1.2 (8–12.5)
32–34 weeks: 10.5 +/−1 (8.6–12.4)
Total serum calcium above 10.8 mg/dL or ionized serum calcium above 5.4 mg/dL.
15. What are some of the causes of hypercalcemia in neonates?
Idiopathic infantile hypercalcemia
Hyperparathyroidism (primary and secondary)
16. How is acute hypercalcemia managed in newborn infants?
Promote diuresis by administering IV fluids (normal saline).
Administer furosemide, and monitor serum electrolytes carefully only after adequate hydration is given.
Hydrocortisone (1 mg/kg every 6 hours) is of value only in chronic situations to reduce intestinal absorption of calcium.
In severe cases dialysis may be required to lower calcium levels while the patient is awaiting definitive treatment of the underlying cause. ∗
17. A 3-day-old infant born small for gestational age at term has a total serum calcium level of 13.2 mg/dL. She was delivered by emergency cesarean section and was diagnosed with supravalvular aortic stenosis. What is the likely diagnosis?
Williams syndrome is the likely diagnosis in an infant with hypercalcemia and supravalvular stenosis who was born small for gestational age. It results from a deletion of the elastin gene on 7q11.23. Affected infants are often described as having “elfin” faces. ∗
18. A term infant is incidentally noted to have a calcium level of 12.2 mg/dL at 4 days of age. Family history reveals that the father has also been evaluated for elevated calcium levels. What would you expect to find on measurement of the infant’s urinary calcium level? What is the most likely diagnosis? What is the appropriate therapy?
The most likely diagnosis is an autosomal dominant mutation of the calcium-sensing receptor, or “hypocalciuric hypercalcemia.” The infant’s urinary calcium level will be inappropriately low for the serum calcium. In the heterozygous state this is generally thought to be a benign condition, and treatment is not indicated. Rare cases of homozygous mutations result in severe neonatal hyperparathyroidism, which is a life-threatening disorder. ∗
Hypomagnesemia and Hypermagnesemia
Intracellular and extracellular types of magnesium reactions are important.
24. What causes magnesium depletion in neonates?
Renal losses of magnesium in acidotic states
Use of nutrient solutions containing insufficient amounts of magnesium
Intestinal wasting of magnesium (rare X-linked condition)
Gastrointestinal losses (through emesis, nasogastric suctioning, and diarrhea)
Prematurity, which increases the risk for magnesium deficiency
Most infants are asymptomatic. On rare occasions the following signs and symptoms may be seen:
Color: pallor, cyanosis, or duskiness
Affect: out of touch with surroundings, apathetic, irritable when disturbed, restless
Eyes: staring with infrequent blinking, oculogyric crises
Heart: tachycardia (bradycardia during apneic episodes)
Respiration: brief apnea, sometimes followed by tachypnea
Neuromuscular system: motor weakness, transient spasticity, abnormal reflexes; if hypocalcemia develops (discussed later), the infant may show signs associated with calcium deficiency, including seizures
Hypomagnesemia usually increases the secretion of PTH, thereby increasing calcium levels. In chronic magnesium-deficient states, however, secretion of PTH is reduced. In such circumstances hypomagnesemia may induce hypocalcemia. ∗
27. What causes hypermagnesemia in neonates?
Maternal treatment with magnesium (for preeclampsia or tocolysis)
Excessive magnesium administration to neonate (e.g., TPN, antacids, treatment of pulmonary hypertension)
In extreme cases cardiorespiratory function ceases, and death ensues.
Thyroid Disorders
Congenital hypothyroidism occurs in 1 in 4000 liveborn infants.
32. What are the embryonic stages of development of the fetal hypothalamic–pituitary–thyroid axis?
Thyroid tissue is first identified at the base of the tongue 16 to 17 days after conception.
By 7 weeks’ gestation the gland has migrated to its final position in the anterior neck and has developed its characteristic bilobed structure.
By 10 weeks’ gestation the fetal thyroid gland is trapping iodine and synthesizing thyroxine (T4).
By 10 weeks’ gestation, the fetal hypothalamus is synthesizing thyrotropin-releasing hormone (TRH). Most fetal TRH, however, is made in extrahypothalamic tissues (e.g., placenta, pancreas). Hypothalamic TRH production does not mature fully until the perinatal period.
By 10 to 12 weeks’ gestation, the fetal pituitary gland is synthesizing thyroid-stimulating hormone (TSH). ∗
The hypothalamic–pituitary–thyroid axis is in place by the end of the first trimester. The thyroid and pituitary glands reach mature secretory capacity by 30 to 35 weeks of gestation. The feedback interrelationship among the units is fully established when hypothalamic TRH maturation is completed by 1 to 2 months after birth. ∗
The amount of T4 secreted by the fetal thyroid gland increases slowly until midgestation (20 to 24 weeks) when, stimulated by increasing amounts of TSH from the fetal pituitary, T4 levels begin to increase more rapidly, reaching a normal adult level by approximately 30 weeks’ gestation. Thereafter T4 increases slowly to high normal levels at term gestation. ∗
The placenta is a barrier to the passages of thyroid hormones and contains enzymes that break down maternal T4 and T3 into inactive metabolites. Only a small percentage of circulating maternal T4 and very little (if any) T3 reaches the fetus. However, the amount of maternal T4 that does cross the placenta is significant. During the first 10 to 12 weeks of gestation, all of the circulating T4 in the fetus is from maternal sources; thus early brain development depends on maternal hormone. Even after the fetus synthesizes its own T4 in the second and third trimesters, maternal T4 is essential for normal neurologic development, including neuronal proliferation and maturation, dendritic arborization, and synapse formation. It accounts for approximately 30% of fetal T4 levels at term. ∗†
The levels of TRH, TSH, T4, free T4, and T3 are lower in premature infants than in term infants, and the postnatal surges of TSH and T4, although qualitatively similar, are blunted. These differences are related directly to gestational age: the lower the gestational age, the lower the levels and responses of thyroid-related hormones ( Table 8-1).
TABLE 8-1
SERUM THYROXINE (µg/dL) AT DIFFERENT GESTATIONAL AGES ∗
Adapted from Cuestas RA. Thyroid function in healthy premature infants. J Pediatr 1978;92:963–7.
The term refers to infants with low birth weight (30 to 35 weeks’ gestation) or very low birth weight (<30 weeks’ gestation), who have an even more attenuated rise in T4, after which T4 levels drop below cord levels in the first week of life. Then they rise gradually over 3 to 6 weeks to approach levels of term infants ( Table 8-2).
TABLE 8-2
THYROID FUNCTION IN PRETERM AND TERM INFANTS ∗
T4, Thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone; free T4, free thyroxine.
http://www.uptodate.com/contents/image?imageKey=PEDS%2F72215&topicKey=PEDS%2F5840&rank=4~150&source=see_link&search=thyroid+function&utdPopup=true
Adapted from Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. J Clin Endocrinol Metab 2004;89:5314.
The premature infant with low T4 and persistently elevated TSH has either transient or permanent hypothyroidism and should be treated with T4 until the nature of the condition becomes clear. However, whether premature infants with low T4 and normal TSH levels should be treated remains controversial. ∗†
43. Does breastfeeding provide needed T4 to premature infants with an immature hypothalamic–pituitary–thyroid axis?
This question has not yet been answered. There are some case reports in the literature suggesting that breastfeeding delays the onset of hypothyroidism, but others argue against that finding.
A heel-stick blood sample is taken at discharge or 3 days of life, whichever is earlier. In most parts of the United States, T4 is measured first, then TSH is measured in samples with the lowest 10% to 29% of T4 results. ∗†
TABLE 8-3
CAUSES OF CONGENITAL HYPOTHYROIDISM AND INCIDENCE OF EACH
From Fisher FA. Disorders of the thyroid in the newborn and infant. In: Sperling MA, editor. Pediatric endocrinology. Philadelphia: Saunders; 1996. p. 57.
Only approximately 1 in 70 neonates born to thyrotoxic mothers exhibit clinical thyrotoxicosis. Such infants may show a phase of transient hypothyroidism caused by antithyroid drugs (half-life, 2 to 3 days), then thyrotoxicosis resulting from maternal TSIs. Transient congenital hypothyroidism can result from transplacental transfer of maternal thyrotopin-blocking antibodies. ∗